We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · September 01, 2021

Safety of Idarucizumab in the Reversal of Dabigatran

Research and practice in thrombosis and haemostasis


Additional Info

Research and practice in thrombosis and haemostasis
Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
Res Pract Thromb Haemost 2021 Jul 01;5(5)e12535, J Abdulrehman, S Zarabi, C Elbaz, K de Wit, Y Lin, M Sholzberg, R Selby

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading